MOUNTAIN VIEW, Calif., July 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced the appointment of Donald J. Kellerman, Pharm.D. to the position of Senior Vice President, Clinical Development and Medical Affairs.

Dr. Kellerman brings to MAP Pharmaceuticals more than 25 years of clinical experience, serving as project leader for multiple products including Flovent(R), Advair(R) and Xopenex(R). Most recently, Dr. Kellerman was Senior Vice President of Development at Inspire Pharmaceuticals, Inc., where he was responsible for all aspects of drug development, including clinical research, regulatory affairs, project management and biostatistics. He also led groups responsible for running several clinical programs in the respiratory, ophthalmology and cardiovascular areas. Prior to joining Inspire, Dr. Kellerman held positions at Glaxo Wellcome, Sepracor, Inc. and Ciba-Geigy Corporation. During his tenure at Glaxo Wellcome, Dr. Kellerman held numerous positions, including Director, Respiratory Clinical Research, and managed the clinical development of inhaled corticosteroids for the treatment of asthma in his role as project leader for Flovent, from first U.S. clinical studies through approval. At Sepracor he led the team responsible for filing the new drug application for Xopenex, an inhaled beta2-agonist used to treat asthma and chronic obstructive pulmonary disease (COPD).

In his new role with MAP Pharmaceuticals, Dr. Kellerman will be responsible for overseeing strategy and execution of MAP Pharmaceuticals' clinical programs including Phase 3 clinical trials for UDB for the potential treatment of pediatric asthma, and for MAP0004 for the potential treatment of migraine.

"MAP Pharmaceuticals is pleased to welcome Don Kellerman to the executive management team at such a pivotal point in our company's history," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "The depth and breadth of Don's experience successfully moving product candidates through various stages of clinical development, FDA approval and product launch will serve the company well as we pursue our goals of commercializing UDB and MAP0004."

Kellerman received his Bachelor of Science and Doctor of Pharmacy from the College of Pharmacy at the University of Minnesota. He has lead or co-authored over 80 publications related to the development of pharmaceutical products.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to product candidates in clinical development. Actual results may differ materially from current expectations based on risks and uncertainties affecting MAP Pharmaceuticals' business, including, without limitation, risks and uncertainties relating to the development, clinical testing and potential commercialization of MAP Pharmaceutical's lead product candidates. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q, filed with the SEC on May 14, 2008, and available at http://edgar.sec.gov.

CONTACT: Mariesa Kemble of WeissComm Partners, +1-608-850-4745,
mkemble@wcpglobal.com, for MAP Pharmaceuticals, Inc.

Web site: http://www.mappharma.com/